Physician profile
Omar Basha
NPI 1831526573
$1,422.27
in general payments reported to CMS, 2019-2025
27 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.14 · 2022: $555 · 2023: $481 · 2024: $106 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.15 | 2022-2024 | Botox |
| Otsuka America Pharmaceutical, INC. | $202.78 | 2025 | Rexulti |
| Amgen INC. | $111.16 | 2022 | |
| Celgene Corporation | $74.33 | 2022-2023 | Zeposia |
| Dentsply Ih Ab | $73.24 | 2023 | Lofric |
| Tg Therapeutics, INC. | $56.69 | 2023 | |
| Ucb, INC. | $54.21 | 2024 | Briviact |
| Sk Life Science, INC. | $53.27 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.07 | 2023 | Gammagard |
| Eisai INC. | $47.86 | 2022-2023 | |
| Merz Pharmaceuticals, LLC | $46.37 | 2022 | |
| Argenx US, INC. | $42.55 | 2023 | Vyvgart |
| Pfizer INC. | $41.31 | 2022-2023 | |
| Blue Earth Diagnostics | $34.99 | 2019 | |
| Biogen, INC. | $33.43 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.22 | 2022 | |
| Horizon Therapeutics Plc | $29.02 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $27.83 | 2023 | Fycompa |
| Medtronic, INC. | $23.82 | 2024 | Linq II |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.19 | 2023 | |
| Amneal Pharmaceuticals LLC | $22.18 | 2022 | |
| Neurocrine Biosciences, INC. | $20.69 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.02 | 2022 | |
| Allergan, INC. | $16.03 | 2022 | |
| Acadia Pharmaceuticals INC | $14.47 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Basha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.